文献速递妇科

年龄对瑞卡帕布疗效、安全性和以患者为中心结局的影响:ARIEL3 一项复发卵巢癌 3 期随机维持治疗研究的事后探索性分析

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
PubMed 文献 · Gynecol Oncol · 2020-08-26

ARIEL3 为 3 期随机对照试验,复发铂敏感卵巢癌患者按 2:1 随机接受瑞卡帕布 600 mg 每日两次或安慰剂维持治疗。事后探索性分析按年龄分层显示,<65 岁和 65-74 岁组无进展生存期显著延长,≥75 岁组数值上延长但未达统计学显著;各年龄亚组生活质量调整无进展生存期和 Q-TWiST 均显著延长,安全性总体相似。

要点

  • 瑞卡帕布维持治疗在 <65 岁和 65-74 岁患者中无进展生存期显著优于安慰剂
  • ≥75 岁患者无进展生存期数值上延长但未达统计学显著
  • 各年龄亚组生活质量调整无进展生存期和 Q-TWiST 均显著延长,安全性总体相似

核心结论

  • 瑞卡帕布在各年龄亚组间的疗效、以患者为中心结局和安全性相似,表明所有符合条件的复发卵巢癌女性均应获得该治疗选择而不论年龄。

研究设计与样本

  • ARIEL3 为 3 期随机对照试验,纳入对末次铂类治疗有反应的铂敏感复发卵巢癌且既往接受过至少 2 线铂类化疗的患者,按 2:1 随机接受瑞卡帕布 600 mg 每日两次或安慰剂。
  • 本分析为事后探索性分析,按年龄分为 <65 岁、65-74 岁和 ≥75 岁三个亚组,评估无进展生存期、以患者为中心结局(生活质量调整无进展生存期和 Q-TWiST)及安全性。

主要发现

  • 研究者评估的无进展生存期:<65 岁组瑞卡帕布 n=237 对比安慰剂 n=117,中位 11.1 个月对比 5.4 个月,HR 0.33(95%CI 0.25-0.43),P<0.0001。
  • 65-74 岁组瑞卡帕布 n=113 对比安慰剂 n=64,中位无进展生存期 8.3 个月对比 5.3 个月,HR 0.43(95%CI 0.29-0.63),P<0.0001。
  • ≥75 岁组瑞卡帕布 n=25 对比安慰剂 n=8,中位无进展生存期 9.2 个月对比 5.5 个月,HR 0.47(95%CI 0.16-1.35),P=0.1593,未达统计学显著。
  • 生活质量调整无进展生存期和 Q-TWiST 在所有年龄亚组中瑞卡帕布均显著长于安慰剂。
  • 瑞卡帕布的安全性在各年龄亚组间总体相似。

临床怎么用

  • 作者认为,所有符合条件的复发卵巢癌女性均应获得瑞卡帕布这一治疗选择,而不论年龄。

局限性

  • 本分析为事后探索性分析。
  • ≥75 岁亚组样本量小(瑞卡帕布 n=25,安慰剂 n=8),其无进展生存期结果未达统计学显著(HR 0.47,95%CI 0.16-1.35,P=0.1593)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 trial ARIEL3, maintenance treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib provided clinical benefit versus placebo for patients with recurrent, platinum-sensitive ovarian cancer. Here, we evaluate the impact of age on the clinical utility of rucaparib in ARIEL3. METHODS: Patients with platinum-sensitive, recurrent ovarian carcinoma with ≥2 prior platinum-based chemotherapies who responded to their last platinum-based therapy were enrolled in ARIEL3 and randomized 2:1 to rucaparib 600 mg twice daily or placebo. Exploratory, post hoc analyses of progression-free survival (PFS), patient-centered outcomes (quality-adjusted PFS [QA-PFS] and quality-adjusted time without symptoms or toxicity [Q-TWiST]), and safety were conducted in three age subgroups (<65 years, 65-74 years, and ≥75 years). RESULTS: Investigator-assessed PFS was significantly longer with rucaparib than placebo in patients aged <65 years (rucaparib n = 237 vs placebo n = 117; median, 11.1 vs 5.4 months; hazard ratio [HR]: 0.33 [95% confidence interval (95% CI) 0.25-0.43]; P < 0.0001) and 65-74 years (n = 113 vs n = 64; median, 8.3 vs 5.3 months; HR 0.43 [95% CI 0.29-0.63]; P < 0.0001) and numerically longer in patients aged ≥75 years (n = 25 vs n = 8; median, 9.2 vs 5.5 months; HR 0.47 [95% CI 0.16-1.35]; P = 0.1593). QA-PFS and Q-TWiST were significantly longer with rucaparib than placebo across all age subgroups. Safety of rucaparib was generally similar across the age subgroups. CONCLUSIONS: Efficacy, patient-centered outcomes, and safety of rucaparib were similar between age subgroups, indicating that all eligible women with recurrent ovarian cancer should be offered this therapeutic option, irrespective of age. https://clinicaltrials.gov/ct2/show/NCT01968213.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Colombo N, Oza AM, Lorusso D, et al. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2020. PMID: 32861537. doi:10.1016/j.ygyno.2020.05.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。